Clinical Trial Update: A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug [Phase 2]

View source ↗

Summary

This update summarizes the completion of a Phase 2 trial evaluating ASP1517 versus darbepoetin in dialysis-dependent chronic kidney disease patients with anemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease
• Chronic Kidney Disease

Drugs mentioned

• ASP1517
• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Renal Anemia Associated With Chronic Renal Failure (CRF) | Phase 2 | Status: COMPLETED